1999•Biochemical PharmacologyRequires access

Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases

Guido J.R. Zaman, Paul M.F. Vink, Antoon A. van der Doelen, Gerrit H. Veeneman, Henri J.M. Theunissen

Open publisher page 24 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Platelet-derived growth factor receptor, ROR1, Receptor tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, Tyrosine kinase, Tropomyosin receptor kinase C, Autophosphorylation, Growth factor receptor

Back to paper search Browse research topics Original source

Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases — Research Paper | ScholarLens